LONDON (Alliance News) - ANGLE PLC said Thursday that new results from a study by the Barts Cancer Institute into the use of its Parsortix system in prostate cancer patients are "encouraging".
The study showed that using the Parsortix system, researchers were able to harvest cells that are clinically relevant in prostate cancer - or circulating tumour cells - from all of the 52 patients involved.
The research suggests the potential for Parsortix to be used to provide a repeatable, non-invasive liquid biopsy for prostate cancer patients. The researchers are continued to expand the work with more patient numbers and undertaking follow-ups of the patients studied so far.
They also will investigate the viability of the cells after their harvest from the Parsortix system and the potential to culture them. They also will look at the molecular biomarkers in the cells harvested in order to assess their potential to predict patient outcome and response to therapies.
"The prospect of deployment of our repeatable, non-invasive liquid biopsy in the treatment of prostate cancer patients in therapy selection and remission monitoring is exciting. These findings are encouraging and we look forward to further developments as soon as possible," said Chief Executive Andrew Newland in a statement.
Shares in ANGLE are trading up 4.4% at 97.05 pence Thursday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Angle (AGL)